Pharma channel feed

In­tas Phar­ma­ceu­ti­cals un­der FDA scruti­ny over 'cas­cade of fail­ure' in over­sight of GMP doc­u­ments

3 years ago
Manufacturing

Genen­tech touts pos­i­tive Phase III da­ta for Tecen­triq/Avastin com­bo in liv­er can­cer

3 years ago
R&D

By sum­mer sol­stice, we'll know the fate of In­ter­cep­t's NASH drug

3 years ago
FDA+

Mer­ck dis­cov­ers 'root cause' of ni­trosamine lev­els in block­buster di­a­betes drugs

3 years ago

Sun Phar­ma picks 'Dr. Pim­ple Pop­per' for ed­u­ca­tion­al ac­ne cam­paign

3 years ago
Marketing

Am­gen tar­gets physi­cians with biosim­i­lars ed­u­ca­tion cam­paign in ad­vance of ex­pect­ed 2023 break­out

3 years ago
Marketing

Up­dat­ed: FDA slaps Op­tum In­fu­sion with a warn­ing let­ter over 'in­san­i­tary' pro­duc­tion con­di­tions

3 years ago
Manufacturing

Bris­tol My­ers de­buts first Op­du­alag cam­paign, adds to its two-com­bo can­cer drug mar­ket­ing

3 years ago
Marketing

Am­gen ex­tends au­toim­mune pact with small Michi­gan biotech

3 years ago
Startups
Deals

J&J re­ports sec­ond HIV vac­cine reg­i­men fail­ure in 18 months

3 years ago
R&D

Ak­ili cuts about 30% of staff in ef­fort to be 'ex­treme­ly lean'

3 years ago
People

ICER: Ma­jor­i­ty of pay­er cov­er­age poli­cies sup­port 'key el­e­ments of fair ac­cess' in for­mu­la­ries

3 years ago

CMS ini­ti­ates cov­er­age analy­sis for provider-ad­min­is­tered PrEP to pre­vent HIV

3 years ago

PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

3 years ago
Deals

Drug name re­view: Sci­ence takes the spot­light in 2022

3 years ago
Marketing

Pfiz­er shifts full port­fo­lio to non-prof­it mod­el in 45 low­er-in­come coun­tries

3 years ago

Fol­low­ing Alzheimer’s drug ap­proval, an­a­lysts dish on what they ex­pect from Bio­gen in 2023 

3 years ago

Mar­ket­ingRx roundup: Eli Lil­ly de­buts un­brand­ed ‘mem­o­ry’ is­sues TV ad; Big Phar­mas amp so­cial me­dia spend­ing

3 years ago
Marketing

Ab­b­Vie, Eli Lil­ly quit UK's vol­un­tary drug pric­ing agree­ment, send­ing 'warn­ing sig­nal' to UK gov­ern­ment

3 years ago

US in­ves­ti­gates po­ten­tial safe­ty sig­nal with Pfiz­er Covid boost­ers

3 years ago
FDA+
Coronavirus

Cal­i­for­nia sues in­sulin heavy­weights, PBMs over 'ex­ces­sive' prices

3 years ago
Law

Ex-Take­da staffer­'s 's­mall hus­tle' ends with ar­rest and $2.3M fraud scheme charge

3 years ago
Law

EMA de­vel­op­ing physi­cian guid­ance for po­ten­tial liv­er dam­age af­ter tak­ing Zol­gens­ma

3 years ago
Cell/Gene Tx

My­ovant, Pfiz­er de­but first brand­ed cam­paign for prostate can­cer med Or­govyx

3 years ago
Marketing
First page Previous page 151152153154155156157 Next page Last page
A service from the Financial Times